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Abstract
Background: In our recent study, Periostin was up-regulated in prostate cancer(PCa) compared with benign
prostate hyperplasia (BPH) by proteomics analysis of prostate biopsies. We investigated the effect of sliencing
Periostin by RNA interference (RNAi) on the proliferation and migration of PCa LNCap cell line.
Methods: All the prostate biopsies from PCa, BPH and BPH with local prostatic intraepithelial neoplasm(PIN) were
analyzed by iTRAQ(Isobaric tags for relative and absolute quantification) technology. Western blotting and
immunohistochemical staining were used to verify Periostin expression in the tissues of PCa. Periostin expression in
different PCa cell lines was determined by immunofluorescence staining, western blotting and reverse transcription
PCR(RT-PCR). The LNCap cells with Periostin expression were used for transfecting shRNA-Periostin lentiviral
particles. The efficancy of transfecting shRNA lentiviral particles was evaluated by immunofluorescence, western
blotting and Real-time PCR. The effect of silencing Periostin expression by RNAi on proliferation of LNCap cells was
determined by MTT assay and tumor xenografts. The tissue slices from theses xenografts were analyzed by
hematoxylin and eosin(HE) staining. The expression of Periostin in the xenografts was deteminned by
Immunohistochemical staining and western blotting. The migration of LNCap cells after silencing Periostin gene
expression were analyzed in vitro.
Results: Periostin as the protein of interest was shown 9.12 fold up-regulation in PCa compared with BPH. The
overexpression of Periostin in the stroma of PCa was confirmed by western blotting and immunohistochemical
staining. Periostin was only expressed in PCa LNCap cell line. Our results indicated that the transfection ratio was
more than 90%. As was expected, both the protein level and mRNA level of Periostin in the stably expressing
shRNA-Periostin LNCap cells were significantly reduced. The stably expressing shRNA-Periostin LNCap cells growed
slowly in vitro and in vivo. The tissues of xenografts as PCa were verificated by HE staining. Additionally, the weak
positive Periostin expressed tumor cells could be seen in the tissues of 6 xenografts from the group of down-
regulated Periostin LNCap cells which had a significant decrease of the amount of Periostin compared to the other
two group. Furthermore, our results demonstrated that sliencing Periostin could inhibit migration of LNCap cells in
vitro.
Conclusions: Our data indicates that Periostin as an up-regulated protein in PCa may be a promising target of
therapeutical intervention for PCa in future.
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Periostin, also named osteoblast-specific factor 2, was
initially identified as a secreted extracellular matrix pro-
tein in the mouse osteoblastic MC3T3-E1cell line[1].
The sequence of Periostin contains a typical signal
sequence, a cysteine-rich domain, a fourfold fasciclin 1-
like (FAS-1) domain and a C-terminal domain[1,2].The
FAS-1 domain, an evolutionarily ancient adhesion
domain, also exists in many proteins such as big-h3, sta-
bling I and II, MBP-70, algal-CAM and Periostin-like
factor. Therefore, all these proteins including Periostin
with the FAS-1 domain belong to the fasciclin family[3].
Additionally, Periostin shares high homology in human
and mouse species: 89.2% amino acid identity in total
and 90.1% identity in their mature forms[4]. Periostin
gene is located on chromosome 3 in mouse compared
with chromosome 13q in human which encodes a Peri-
ostin of 835 amino acids with a MW of 90 kDa[5].
Periostin can interact with other extracelluar matrix
proteins such as fibronectin, tenascin C, collagen type I,
collagen type V and heparin. And, it can induce integrin-
dependent cell adhesion and motility by binding to avb3
or avb5 integrins[6]. Periostin is highly expressed in
many normal tissues such as periosteum, perichondrium,
periodontal ligaments, the fascia of muscles, articular sur-
faces of the epiphyseal cartilage and joint ligaments[7-9].
Thus, it is perceived as playing a potential role in the for-
mation and structural maintenance of all these tissues[9].
Additionally, it has been reported that the expression of
Periostin is correlated with the development of the heart
and some heart diseases[10,11].
Recently, The overexpression of Periostin has been
found in various human cancers including non-small-
cell lung cancer, ovarian cancer, breast cancer, colon
cancer, pancreatic cancer, liver cancer, oral cancer, head
and neck cancer and neuroblastoma[12-20]. It is
thought that Periostin stimulates tumor cell growth by
preventing apoptosis and promoting angiogenesis and
enhances the survival of tumor cells via the Akt/PKB
pathway[13,19]. Besides, Periostin always plays a great
role in tumor invasion and metastasis[12,15,19].
In our recent study, we analyzed the samples of pros-
tate biopsies from the patients with prostate cancer
(PCa), benign prostate hyperplasia (BPH) and BPH with
local prostatic intraepithelial neoplasm(PIN) by proteo-
mics analysis using iTRAQ(Isobaric tags for relative and
absolute quantification) combined with 2DLC-MS/MS
(two-dimensional liquid chromatography-tandem mass
spectrometry) to find the biomarkers of PCa. A total of
760 proteins were identified from 13787 distinct pep-
tides. Among the 760 proteins, Prostate specific antigen
and Prostatic acid phosphatase are well-known proteins
enjoying clinical application. Based on the condition of
screening differentially expressed proteins(the fold
change cutoff ratio<0.66 or >1.50 as criterion to identify
proteins of differential expression (P <0.05) was
adopted), 20 proteins were significantly up-regulated
and 26 were significantly down-regulated in the 116
labeled PCa samples compared with the 114 labeled
BPH samples (Additional file 1, Table S1). Among the
differentially expressed proteins, Periostin as the protein
of interest was shown 9.12 fold up-regulation in PCa
compared with BPH (Additional file 2, Figure S1)[21].
However, there are a little studies about the expres-
sion of Periostin in PCa. So, in our whole study, we
focused on the expression and function of Periostin in
PCa. The expression of Periostin was verificated by wes-
tern blotting. The results revealed a significant increase
of the amount of Periostin in PCa compared to BPH
(Additional file 3, Figure S2B). Furthermore, immuno-
histochemical staining was performed to evaluate Perios-
tin expression in the stromal or epithelial cells of
prostate (Additional file 3, Figure S2A). Benign prostate
glands expressed positive stromal Periostin in only 5/20
cases and positive epithelial Periostin in 8/20 cases;
whereas the stroma of PCa was positive in 16/20 cases
and the epithelium of PCa was positive in 12/20 cases.
Statistical significance was observed for the stromal
expression of Periostin between PCa and BPH (P <0.01).
However, there was no statistical significance for the
epithelial expression of Periostin between PCa and BPH
(Additional file 4, Table S2)[21].
Here, Periostin was proposed to be a novel therapeutic
target for PCa. Furthermore, the expression of Periostin
in different PCa cell lines and the effect of sliencing
Periostin by RNAi(RNA interference) on the prolifera-
tion and migration of PCa LNCap cells were studied.
Materials and methods
The identification and verification of Periostin
All the prostate biopsies from PCa, BPH and BPH with
local PIN were analyzed by iTRAQ technology. Periostin
was identified as a differential expressed protein of PCa
compared to BPH and then the overexpression of Peri-
ostin in PCa was verificated by western blotting and
immunohistochemical staining. The above processes
have been reported by our group[21]. The details on the
identification and verification of Periostin have been
provided in the additional materials. The study was
approved by the local ethics committee of Huashan
Hospital of Fudan University.
Cell culture
Human PCa cell lines:LNCap,DU-145,PC3,22RV1 were
obtained from the Cell Bank of Chinese Academy of
Sciences(Shanghai) and maintained in RPMI 1640 with
10% of fetal bovine serum, 100 u/mL of penicillin, and
50 mg/mL streptomycin (Beyotime, China) at 37°C in a
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week.
shRNA lentiviral particles transfection
shRNA-Periostin lentiviral particles and control GFP
lentiviral particles were obtained from Santa Cruz Bio-
technology, Inc(USA). According to the instruction on
the lentiviral particles, the cells were plated in a 12-well
plate 24 hours prior to viral infection and incubated
with 1 ml of complete optimal medium (with serum and
antibiotics) overnight. The media in the plate wells was
removed and replaced with 1 ml of Polybrene/media
mixture(Santa Cruz,USA) per well. The cells were
infected by adding the shRNA lentiviral particles to the
culture. The plates were gently swirled to mix and incu-
bate overnight. The stable clones expressing the shRNA
cells were selected and divided 1:3 and subsequently
incubated for 48 hours in complete medium. Then, the
stable clones expressing the shRNA cells were selected
via Puromycin dihydrochloride (Santa Cruz, USA).The
culture medium was replaced with fresh puromycin-
containing medium every 3-4 days until the resistant
colonies can be identified. Several colonies were picked
and analyzed for stable shRNA.
Immunofluorescence staining for detecting efficancy of
shRNA lentiviral particles transfection
Immunofluorescence staining was used for immunophe-
notype characterization of Periostin in different cell
lines. The cells were fixed with 4% paraformaldehyde for
20 min, blocked with 5% bovine serum album for 45
min, then incubated with primary monoclonal antibody
(1:200) at room temperature for 1 h. Cells were washed
three times in PBS and incubated with corresponding
secondary antibodies (1:200) for 2 h at room tempera-
ture. After second rinsing in PBS, The nuclei were
stained with 4’, 6-diamidino-2-phenylindole(DAPI,
Sigma, USA) for 5 min at room temperature and then
the cells were tested with fluorescence microscopy.
Western blotting for detecting Periostin expression in
PCa cell lines
The cells without treatment and the transfected cells
were washed with PBS and harvested. Cell lysates were
isolated by the protein extraction buffer (containing 150
mM NaCl, 10 mM Tris(pH 7.2), 5 mM EDTA, 0.1% Tri-
ton X-100, 5% glycerol, and 2% SDS), and then incu-
bated at 4°C for 30 min. After centrifugation at 12,000
rpm for 30 min, the protein concentration in cell lysates
was determined using Bradford assay. Proteins were
denatured in sample buffer containing 2-mercaptoetha-
nol and bromophenol blue for 10 min at 95°C. Equal
amount of proteins (50 ug) was fractionated using 8 or
12% SDS-PAGE and transferred to PVDF membranes.
After blocking with 5% non-fat milk, the membranes
were incubated overnight at 4°C with the primary anti-
body. Then, the membranes washed with PBS three
times were incubated in secondary antibody at room
temperature. The intensity of target protein was
detected using the enhanced chemiluminescence detec-
tion system.
Reverse transcription PCR (RT-PCR) for detecting Periostin
mRNA expression in PCa cell lines
Total RNA from PCa cell lines was extracted by the Tri-
zol according to the instructions of manufacturer. The
reverse transcription of RNA to cDNA was carried out
using random primers of the SuperScript III First-Strand
Synthesis SuperMix kit (Invitrogen).The forward and
reverse primers were synthesized by Ying Jun Biotechn-
ology,Inc (Shanghai) and presented as follows: Periostin
(forward, 5’ AGGCAAACAG CTCAGAGTCTTCGT 3’
and reverse, 5’ TGCAGCTTCAAGTAGGCTGAGGAA
3’). b-actin (forward, 5’ CTGGCACCACACCTTCTA-
CAATGA 3’ and reverse, 5’ TTAATGTCACGCAC-
GATTTCCCGC 3’). For each pair of primers, the
following protocol was applied. Initial denaturing: 2 min-
utes at 95°C, 40 cycles with denaturing at 94°C for 30 sec-
onds, ananealing at Tm for 30 seconds and extension at
72°C for 1 minute. Products from PCR were separated by
electrophoresis on a 2% agarose gel and then visualized
witheth-idium bromide under ultraviolet light.
Real-time PCR for detecting Periostin mRNA expression
after shRNA lentiviral particles transfection
The procedures of the RNA extraction and the reverse
transcription of RNA to cDNAa r es i m i l a rt ot h ea b o v e
description. Quant qRT-PCR (Sybr green I) Kit (Tian-
gen, Beijing) and qRT-PCR system (ABI, USA) were
applied. The data was analyzed by ABI Prism 7300 SDS
Software (ABI,USA) and the method of ΔΔct was used
to calculate Periostin mRNA expression and the silence
efficacy. The silence efficacy was determined by the for-
mula: 1-2
-ΔΔct.
MTT assay
Cell proliferation was measured with the 3-(4,5-
dimethylthiazol-2-yl) -2,5-diphenyl-ltetrazolium bromide
(MTT, Sigma, USA) method. 200 μl of cells were seeded
in a 96-well plate at a density of 4 × 10
3 cells per well
and were subsequently incubated for 24 h to allow
attachment. After incubation for 2,3,4,5,6 days, 20 μl
MTT solution (5 mg/mL in PBS) were added to the
wells for 4 h incubation before termination by aspiration
of the media. The cells were then lysed with 150 μl
dimethylsulfoxide (DMSO, Sigma, USA). The absor-
bance of the suspension was measured at 570 nm on an
ELISA reader.
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The Millicell chambers (pore size 12 μm, insert size 12
mm, Millipore,USA) were set into 24-well plates which
contained the supernatant of the cells(10
6)f o r4 8h
incubation. The Millicell chambers were removed from
the well, and the matrigel was carefully removed from
the membrane with a cotton wool stick. Then the Milli-
cell was washed three times with PBS, fixed in 3% glu-
taral and stained with hematoxylin staining. The
membrane was then removed from the Millicell, set
upside down on a glass slide and covered with a cover-
slip. Cells were counted under the microscope at 200 ×
magnification. Eight fields were counted per membrane.
Tumorigenicity in vivo
6-week-old male nude mice used for subcutaneous
implantation of LNCaP cells were obtained from the
Laboratory Animal Centre of Fudan University and
housed in the laminar flow cabinets. Stably expressing
shRNA-Periostin cells, control GFP cells and the cells
without treatment were harvested and resuspended at 1
×1 0
6/100 μLi nP B S .5 0 0μL suspension was then
injected into the oxter of these mice (n = 6 for each
group). Tumor growth was measured twice every week.
After 42 days, all these mice were sacrificed and the
tumors were dissected. The tissue slices from theses
xenografts were analyzed by hematoxylin and eosin(HE)
staining. The final tumor burden was measured by
weight on the last day of the experiment. The size was
determined by the formula: 0.5236L1(L2)
2(L1:long dia-
meter, L2:short diameter).
Immunohistochemical staining for detecting Periostin
expression in the xenografts
Immunohistochemical staining was performed to evalu-
ate Periostin expression in these xenografts. Each slide
was deparaffinized and rehydrated according to standard
protocol, and treated with 10 mM sodium citrate buffer
in a microwave pressure cooker at 120°C for 15 min.
Sections were then immersed in 3% hydrogen peroxide
and nonspecified binding was blocked in 5% normal
goat serum. A polyclonal anti-Periostin was diluted
1:100. Immunohistochemical staining was conducted
following the avidin-biotin peroxidase complex method
with diaminobenzidine as a chromogen. Slides were
counterstained with haematoxylin, dehydrated and
mounted. Brown cytoplasmic staining of stromal or
tumor cells was considered positive.
Western blotting for detecting Periostin expression in the
xenografts
To determine Periostin expression, the fresh tissue sam-
ples of these xenografts were analyzed by western blot-
ting. The tissue samples were lysed in the protein
extraction buffer (150 mM NaCl, 10 mM Tris(pH 7.2), 5
mM EDTA, 0.1% Triton X-100, 5% glycerol, and 2%
SDS) after tripsis in liquid nitrogen and then incubated
at 4 °C for 30 min. After centrifugation at 12,000 rpm
for 30 min, the protein concentration in tissue homoge-
nate was determined using Bradford assay. The pro-
cesses of western blotting are similar to the above
description.
Statistics
The results are expressed as Mean±SD. Statistical analy-
sis was performed using t-test or X
2-test by SPSS 13.0.
The difference is considered statistically significant
when the P value is <0. 05.
Results
The expression of Periostin in PCa cell lines
The immunofluorescence staining showed that all the
cell lines were negative except for the LNCap cells (Fig-
ure 1C). Similar results were confirmed by western blot-
ting. Periostin was not detected in any of prostate cell
lines, except for LNCap cells (Figure 1B). Concerning
the expression of periostin mRNA in PCa cell lines, RT-
PCR analysis showed a consistency with the expression
of periostin protein (Figure 1A).
The efficacy of shRNA lentiviral particles transfection
LNCap cells were chosen to continue the research of
sliencing Periostin. The shRNA-Periostin lentiviral parti-
cles and control GFP lentiviral particles were directly
obtained stably expressing among which cells with stable
expression were identified (Figure 2A). LNCap cells
transfected with the lentiviral particles showed green
fluorescence under the fluorescence microscope. Both
kinds of the infected LNCap cells showed above 90%
Figure 1 The expression of Periostin in different PCa cell lines.
A: The results of RT-PCR analysis showed that the expression of
Periostin mRNA was only detected in LNCap cells. B: The similar
expression of Periostin protein in LNCap cells were confirmed by
Western blot assay. C: The immunofluorescence staining indicated
that green fluorescence only presented in LNCap cells and the
other cell lines were negative.
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used to analyze the level of Periostin mRNA after trans-
fecting shRNA lentiviral particles to LNCap cells. Figure
2B-b indicated that Periostin mRNA level of LNCap
cells which stably expressed shRNA-Periostin was
decreased by nearly 80% compared with the LNCap
cells without treatment while control GFP lentiviral par-
ticles had no influence on the Periostin mRNA level of
LNCap cells. As was expected, the Periostin protein
expression was significantly reduced by shRNA-Periostin
lentiviral particles (Figure 2B-a).
Sliencing Periostin inhibits the proliferations of LNCap
cells in vitro and in vivo
To study the influence of sliencing Periostin on cell pro-
liferation in vitro, we drew cell growth curves of LNCap
cells based on the results of MTT. The results illu-
strated that the stably expressing shRNA-Periostin
LNCap cells started to grow slowly from the third day
(Figure 3A). There was significant difference in growth
rates on 3 4,5,6 days compared with normal LNCap
cells and control GFP LNCap cells (Figure 3A).
Furthermore, to determine the effects of sliencing
Periostin on LNCap cells in vivo, down-regulated Peri-
ostin LNCap cells, normal LNCap cells and control GFP
LNCap cells were implanted into the oxter of the nude
mice. After 42 days, the apparente tumors could be seen
in the oxter of all these mice and no mouse was died
(Figure 4A). After sacrificing these mice and dissectting
the tumors, the tissue slices from theses xenografts were
analyzed by HE staining. The HE staining of these xeno-
grafts showed that the typical tumor cells of PCa scat-
tered in clusters or nests with the enlarged and atypia
nuclei containing prominent nucleoli which were iso-
lated by redudant tumor-stroma(Figure 4B)
The growth curves of the tumors illustrated that the
stably expressing shRNA-Periostin LNCap cells also
grew slowly in vivo (Figure 3B). As shown in Figure 5A,
the mean size of the tumors in the group of down-regu-
lated Periostin LNCap cells was significantly smaller
than the other two groups. The minimum tumor could
been seen in the group of down-regulated Periostin
LNCap cells and the maximum tumor could be found
in the group of normal LNCap cells(Figure 5A).
Figure 2 The efficacy of shRNA lentiviral particles transfection. A: Compared with LNCap cells transducted with the control GFP lentiviral
particles (a) and shRNA-Periostin lentiviral particles(c) under common microscope, it could be seen that the effective rate of trusduction was
more than 90% under fluorescence microscope(b and d). B: a:The Periostin protein expression was significantly reduced by shRNA-Periostin(P
<0.05). b:The level of mRNA of Periostin after transducting shRNA-Periostin lentiviral particles was decreased by nearly 80% (P <0.05). Control GFP
lentiviral particles had no influence on the Periostin expression of LNCap cells.
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nificant decrease in the tumor burden (Figure 5B).
The expression of Periostin in the xenografts
Immunohistochemical staining was performed to evalu-
ate Periostin expression in the stromal or tumor cells of
the xenografts. The tissues of all 18 xenografts expressed
strong positive Periostin in the stroma(Figure 6A) and
the tissues of 12 xenografts from the groups of normal
L N C a pc e l l sa n dc o n t r o lG F P - L N C a pc e l l sa l s o
expressed strong positive Periostin in the tumor cells
(Figure 6A-a,6b). But, the tumor cells of the tissues of 6
xenografts from the group of down-regulated Periostin
LNCap cells showed weak positive Periostin expression
(Figure 6A-c,6d). Furthermore, the relative expression
level of Periostin was detected by western blotting. The
results revealed a significant decrease of the amount of
Periostin in the xenografts from the group of down-
regulated Periostin LNCap cells compared to the xeno-
grafts from the other two groups (Figure 6B).
Sliencing Periostin inhibits migration of LNCap cells in
vitro
To calculate the number of migrated cells stained with
hematoxylin on the underside of the Millicell by micro-
scope. For the LNCap cells of down-regulated Periostin, the
number of migrated cells was 20.25 ± 6.71. For the normal
LNCap cells and control GFP LNCap cells, the number was
37.38 ± 5.53 and 35.38 ± 6.57 respectively (Figure 7).The
results indicated that sliencing Periostin significantly inhib-
ited migration of LNCap cells in vitro (P <0.05).
Discussion
The development of proteomics may help us better under-
stand the pathological pathways of diseases and identify
more promising targets. iTRAQ was developed by Applied
Biosystems Incorporation in 2004. It labels global peptide,
preserves post-translational modification information and
makes quantitative proteomics analysis of 4 samples
simultaneously under the same experimental conditions,
Figure 4 The subcutaneous xenografts of LNCaP cells.A :T h e
nude mice with the subcutaneous xenografts of LNCaP cells were
successfully established. The 6 nude mice listed belongs to the
group of subcutaneous xenografts of normal LNCaP cells The
subcutaneous xenografts can be seen in the oxter of the nude
mice. B: The HE staining of these xenografts showed that the typical
tumor cells of PCa scattered in clusters or nests with the enlarged
and atypia nuclei containing prominent nucleoli which were
isolated by redudant tumor-stroma.
Figure 3 Sliencing Periostin inhibits the proliferations of LNCap cells in vitro and vivo.A :G r o w t hc u r v e so fL N C a pc e l l sb yM T T .R e d
represented LNCap cells transfected with shRNA-Periostin lentiviral particles. Green and pink represented normal LNCap cells and control GFP
LNCap cells,respectively. From day 3, the stably expressing shRNA-Periostin LNCap cells started to grow slowly(P <0.05). B: The stably expressing
shRNA-Periostin LNCap cells grew slowly in vivo. Red represented LNCap cells transfected with shRNA-Periostin lentiviral particles. Blue and pink
represented normal LNCap cells and Control GFP LNCap cells, respectively.
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dimensional gel electrophoresis), ICAT (isotopecoded affi-
nity tags) and SILAC (stable isotope labeling by amino
acids in cell culture)[22,23]. The results of our recent
study indicated a strong proof of the reliability of iTRAQ
approach in the proteomics analysis of PCa. Periostin as
an up-regulated protein has been found to be overex-
pressed in the stroma of PCa. Additionally, the correlation
between Periostin and PCa has been studied. Tsunoda etal
[24] defined gene expression signatures that are associated
with 3-dimensional culture of prostate epithelial cells and
extracted Periostin gene which was further evaluated using
clinically PCa specimens. Their results demonstrated that
Periostin expression was increased in the early stages of
PCa (Gleason score 6-7), but not in the advanced stages of
PCa. Furthermore, the positive ratio observed for the
expression of PCa in tumor stroma was significantly corre-
lated with the degree of malignancy. Tischlel etal [25]
determined Periostin expression in the stromal and epithe-
lial compartment of PCa, as well as the correlation with
clinical data including patient follow up data in a larger
cohort. Their results revealedt h a ti n c r e a s e dp e r i o s t i n
expression in carcinoma cells was significantly associated
with high Gleason score and advanced tumor stage. Addi-
tionly, the high stromal periostin expression was asso-
ciated with higher Gleason scores and shortened PSA
relapse free survival times. All the results of the above stu-
dies including ours indicate that periostin may be not only
a promising biomarker for the prognosis of PCa but also a
potential target for therapeutical intervention[21,24,25].
Periostin overexpression in human tumors can
enhance tumor growth and always increase tumor inva-
sion and metastasis[9,12]. The goal of our study is to
observe the effect of sliencing Periostin by RNAi on the
proliferation and migration of human PCa cell lines.
RNAi is the sequence-specific gene-silencing induced by
double-stranded RNA (dsRNA), and gives information
about gene function in a quick, easy and inexpensive
Figure 5 The burden of the xenografts.A : T h et u m o r so ft h e
xenografts were listed, micr-arrow represented the minimum tumor
and pykno-arrow represented the maximum tumor. B: The mean
burden of tumors was minimum in the group of LNCap cells with
down-regulated Periostin(P <0.05).
Figure 6 The expression of Periostin in the xenografts. A: The tissues of 12 xenografts from the groups of normal LNCap cells and control
GFP-LNCap cells expressed strong positive Periostin in the stroma and tumor cells (a ×100, b ×200). But, the tissues of 6 xenografts from the
group of down-regulated Periostin LNCap cells showed strong positive Periostin expression in the stroma and weak positive Periostin expression
in tumor cells(c ×100, d ×200). B: The expression level of Periostin in the xenografts from the group of down-regulated Periostin LNCap cells
significantly decreased compared to the xenografts from the other two groups.
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used to induce RNAi in vertebrate cells, providing a tool
to create continuous cell lines in which suppression of a
target gene can be stably maintained[27]. Recently,
many researchers have used plasmid and viral vectors
for shRNA transcription, both in vitro and in vivo[26].
In our study, synthesized shRNA-Periostin lentiviral par-
ticles as a pool of concentrated, transfection-ready viral
particles contain 3 target-specific constructs that encode
19-25nt (plus hairpin) shRNA designed to knock down
gene expression at an efficacy of over 90%. Western
blotting and Real-time PCR assays were used to evaluate
the Periostin expression at protein level and mRNA
level after transfection. Periostin mRNA level of LNCap
cells with stably expressed shRNA-Periostin was
decreased by nearly 80% compared with that of the
LNCap cells without treatment. As was expected, the
significantly lower level of the Periostin protein caused
by shRNA-Periostin lentiviral particles was consistent
with the change of Periostin mRNA level (Figure 2B).
Several studies have indicated that Periostin mRNA and
protein are not expressed in several human cancer cell
lines [11,28,29]. In our study, four different PCa cell lines:
DU145, PC3, 22RV1 and LNCap were used to evaluate the
expression of Periostin in PCa cells. Our results indicated
that Periostin mRNA and protein were only expressed in
the PCa LNCap cell line (Figure 1). LNCap cell line was
isolated in 1977 by Horoszewicz et al from a needle aspira-
tion biopsies of the left supraclavicular lymph node of a
50-year-old Caucasian male with confirmed diagnosis of
metastatic prostate carcinoma. The LNCap cells respon-
sive to 5-alpha-dihydrotestosterone can produce prostatic
acid phosphatase and prostate specific antigen[30]. So,
LNCap cell line is the best PCa cell line which can simu-
late biological behavior of PCa. The expressed differences
of Periostin in PCa cell lines may be caused by different
biological characteristics of those cell lines.
Though Periostin can promote the proliferation and the
survival of several human cancer cell lines in vitro by indu-
cing Akt/PKB pathway[12]. Some studies demonstrate that
Periostin overexpression does not promote proliferation of
human cancer cell lines including 293T, B16F1,MDA-MB-
231,HSC2 and HSC3[4]. In our study, we have found that
both the protein and mRNA of Periostin were only
expressed in the PCa LNCap cell line(Figure 1). As a fol-
low-up, we tried to explore the effect of sliencing Periostin
on the proliferation of LNCap cells. MTT assay in vitro
and tumorigenicity in vivo were used to evaluate the effect.
As a result, stably expressing shRNA-periostin LNCap
cells growed slowly in vitro and in vivo (Figure 3), which
indicated that sliencing Periostin inhibited the prolifera-
tion of LNCap cells in vitro and in vivo.
The expression of Periostin in the xenografts was
determined by immunohistocheical staining and western
blotting. As a result, the weak positive Periostin
expressed tumor cells could be seen in the tissues of 6
xenografts from the group of down-regulated Periostin
LNCap cells which had a significant decrease of the
amount of Periostin compared to the other two group
(Figure 4). So, The decreased expression level of Periostin
in the xenografts from the group of down-regulated Peri-
ostin LNCap also indicated the effect of RNAi in vivo.
Additionally, the strong positive stromal Periostin expres-
sion in the tissues of all 18 xenografts revealed tumor-
stroma interaction. Epithelial-mesenchymal transition
(EMT), an important form of tumor-stroma interaction,
plays a great role in tumor invasion and tumor metastasis
[31]. Periostin has been reported to correlate with the
process and facilitate the migration of the cancer cells
[ 1 8 ] .A c c o r d i n gt oo u rr e s u l t s ,sliencing Periostin could
inhibit migration of LNCap cells in vitro (Figure 5) which
in turn may be involved in the change of EMT.
Conclusion
Periostin as an up-regulated protein in PCa was identi-
fied by proteomics analysis of the samples of prostate
biopsy, and then its overexpression in the stroma of
PCa was confirmed in our recent study. Here, our study
indicates that Periostin is only expressed in LNCap cell
line and stably expressing shRNA-Periostin LNCap cells
can be obtained by transfecting shRNA-Periostin lenti-
viral particles. Sliencing Periostin expression by RNAi
can inhibit the proliferation and migration of LNCap
cells. Therefore, Periostin m a yb eap r o m i s i n gt a r g e to f
therapeutical intervention for PCa in future.
A list of abbreviations used in the paper
2DLC-MS/MS: two-dimensional liquid chromatography-
tandem mass spectrometry; BPH: benign prostate
Figure 7 The migration of LNCap cells was detected by
Millicell. The number was 37.38 ± 5.53, 35.38 ± 6.57, respectively
for the nomal LNCap cells and control GFP LNCap cells. But, the
number of migrated cells was 20.25 ± 6.71 in the group of LNCap
cells with down-regulated Periostin(P <0.05).
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Page 8 of 10hyperplasia; HE: hematoxylin and eosin; iTRAQ: isobaric
tags for relative and absolute quantification; PAP: pro-
static acid phosphatase; PCa: prostate cancer; PIN: pro-
static intraepithelial neoplasm; PSA: prostate specific
antigen; RNAi: RNA interference; shRNA: short-hairpin
RNA.
Additional material
Additional file 1: Table S1. Differentially expressed proteins
between 116(PCa) and 114(BPH). Based on the condition of screening
differentially expressed proteins (the fold change cutoff ratio<0.66 or
>1.50 as criterion to identify proteins of differential expression (P <0.05)
was adopted), 20 proteins were significantly differentially up-regulated
and 26 were significantly down-regulated in the 116 labeled PCa
samples compared with the 114 labeled BPH samples.
Additional file 2: Figure S1. A representative MS/MS spectrum of
Periostin. The relative ratios of Periostin between 116(PCa) and 114(BPH)
was 9.12. Periostin was identified with 13 peptides above the 95%
confidence. This Figure displays the MS/MS spectrum of one peptide
from Periostin. The peptide sequence: IITGPEIK is shown(The peptides
above the 95% confidence are colored green and the peptides in the
other colors have lower confidence). BPH samples were labeled with 114
tags, PCa samples were labeled with the 116 tags, and PIN samples were
labeled with 117 tags. The peptide fragments including b-ion and y-ion
series are shown in A and B. The quantitation information of the peptide
is shown in C.
Additional file 3: Figure S2. The expression of periostin in
malignant and benign prostate tissue. A: Immunohistochemical
staining of periostin in PCa and BPH. Negative epithelial and stromal
periostin expression in BPH(a) and PCa(c). Positive epithelial and stromal
periostin expression in BPH(b) and PCa(d). B: The results of western
blotting revealed a significant increase of periostin amount in PCa
compared to BPH(P <0.05).
Additional file 4: Table S2. Epithelial and stromal expression of
periostin in PCa and BPH. Benign prostate glands expressed positive
stromal Periostin in only 5/20 cases and positive epithelial Periostin in 8/
20 cases; whereas the stroma of PCa was positive in 16/20 cases and the
epithelium of PCa was positive in 12/20 cases. Statistical significance was
observed for the stromal expression of Periostin between PCa and BPH
(P <0.01). However, there was no statistical significance for the epithelial
expression of Periostin between PCa and BPH.
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